Podcasts > Archived Podcasts > Industry Focus
This show is no longer producing new episodes. Check out our other shows.
Industry Focus
Healthcare: A Surprising Reversal for Alkermes, Celldex's Super Bad News, and J&J's Q1 in Review
Apr 18, 2018 (26:07)
Alkermes’ ALKS-5461 gets a do-over, Celldex's lead drug is a bust, and the good and bad of Johnson & Johnson's Q1 earnings report.
Thanks to Blooom for supporting Industry Focus. Get a month free with blooom401k.com/fool and code fool.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.